PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-13
DOI
10.1186/s13046-019-1466-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble?
- (2019) Pedro Moutinho-Ribeiro et al. Frontiers in Endocrinology
- PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio
- (2019) Yi-Bo Qiu et al. Scientific Reports
- PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway
- (2019) Jing Wang et al. LIFE SCIENCES
- EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC
- (2019) Yalei Yin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression
- (2019) Weidong Shi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells
- (2019) Bethtrice Elliott et al. CANCER LETTERS
- PES1 is a critical component of telomerase assembly and regulates cellular senescence
- (2019) Long Cheng et al. Science Advances
- Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome
- (2019) Natalia Anahi Juiz et al. Frontiers in Oncology
- Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival
- (2019) Ariella M. Altman et al. ANNALS OF SURGICAL ONCOLOGY
- Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications
- (2019) Michal J. Dabrowski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CDK5-mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis
- (2019) Fuqiang Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo
- (2018) Carmela Ciccarelli et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression
- (2018) Dewan Md Sakib Hossain et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of Cyclin-dependent Kinase 5 - a Novel Strategy to Improve Sorafenib Response in HCC Therapy
- (2018) Maximilian A. Ardelt et al. HEPATOLOGY
- PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma
- (2018) Ping Fan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma
- (2018) Bo Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Histone acetylation and histone deacetylation in neuropathic pain: An unresolved puzzle?
- (2017) Ravneet Kaur Khangura et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion
- (2017) Xin Jin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Targeting Cancer Cells with BET Bromodomain Inhibitors
- (2017) Yali Xu et al. Cold Spring Harbor Perspectives in Medicine
- A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
- (2017) Shu-Fu Lin et al. PLoS One
- Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
- (2016) Elisabeth Hessmann et al. GUT
- Concepts to Target MYC in Pancreatic Cancer
- (2016) M. Wirth et al. MOLECULAR CANCER THERAPEUTICS
- Epigenomic regulation of oncogenesis by chromatin remodeling
- (2016) R Kumar et al. ONCOGENE
- Nucleolar protein PES1 is a marker of neuroblastoma outcome and is associated with neuroblastoma differentiation
- (2015) Masato Nakaguro et al. CANCER SCIENCE
- Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
- (2015) C. Hu et al. MOLECULAR CANCER THERAPEUTICS
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies
- (2015) E Hessmann et al. ONCOGENE
- Repression of PES1 expression inhibits growth of gastric cancer
- (2015) Jieping Li et al. TUMOR BIOLOGY
- MYC, Metabolism, and Cancer
- (2015) Z. E. Stine et al. Cancer Discovery
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- An Overview of MYC and Its Interactome
- (2014) M. Conacci-Sorrell et al. Cold Spring Harbor Perspectives in Medicine
- PES1 differentially regulates the expression of ERα and ERβ in ovarian cancer
- (2013) Jieping Li et al. IUBMB LIFE
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- PES1 promotes breast cancer by differentially regulating ERα and ERβ
- (2012) Long Cheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting PES1 for restoring the ERα/ERβ ratio in breast cancer
- (2012) Christoforos Thomas et al. JOURNAL OF CLINICAL INVESTIGATION
- Chromatin-modifying enzymes as modulators of reprogramming
- (2012) Tamer T. Onder et al. NATURE
- Mutation of pescadillo Disrupts Oligodendrocyte Formation in Zebrafish
- (2012) Timothy Simmons et al. PLoS One
- Transcriptional Regulation of PES1 Expression by c-Jun in Colon Cancer
- (2012) Wei Xie et al. PLoS One
- Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
- (2011) Georg Feldmann et al. CANCER BIOLOGY & THERAPY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Cdk5-mediated Phosphorylation of c-Myc on Ser-62 Is Essential in Transcriptional Activation of Cyclin B1 by Cyclin G1
- (2008) Haeng Ran Seo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started